Medicina
Facultad
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (268)
2024
-
A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 695-702
-
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
European Urology
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
2023
-
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2
Human Mutation, Vol. 2023
-
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 2007-2019
-
Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry
Genome Medicine, Vol. 15, Núm. 1
-
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival
Cancer Medicine, Vol. 12, Núm. 15, pp. 16142-16162
-
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 21, pp. 3663-3669
-
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
Oncologist, Vol. 28, Núm. 6, pp. 501-509
-
Comparison of the Accuracy of the 7-Item HADS Depression Subscale and 14-Item Total HADS for Screening for Major Depression: A Systematic Review and Individual Participant Data Meta-Analysis
Psychological Assessment, Vol. 35, Núm. 2, pp. 94-114
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients with Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Journal of Clinical Oncology, Vol. 41, Núm. 1, pp. 43-53
-
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
Annals of Oncology
-
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267
-
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib
European urology, Vol. 83, Núm. 3, pp. 200-209
-
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Journal of Hematology and Oncology, Vol. 16, Núm. 1
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935
-
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
Journal of Medical Genetics, Vol. 60, Núm. 12, pp. 1186-1197
-
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Cancers, Vol. 15, Núm. 16
-
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 35, pp. 5363-5375